Last reviewed · How we verify
Ovitrelle® [r-hCG alfa]
Ovitrelle is a recombinant human chorionic gonadotropin (r-hCG) that binds to luteinizing hormone (LH) receptors to trigger final oocyte maturation and ovulation.
Ovitrelle is a recombinant human chorionic gonadotropin (r-hCG) that binds to luteinizing hormone (LH) receptors to trigger final oocyte maturation and ovulation. Used for Final oocyte maturation induction in women undergoing assisted reproductive technology (ART) cycles, Ovulation induction in anovulatory women.
At a glance
| Generic name | Ovitrelle® [r-hCG alfa] |
|---|---|
| Also known as | Ovitrelle®, Ovidrel® |
| Sponsor | Merck KGaA, Darmstadt, Germany |
| Drug class | Gonadotropin; LH receptor agonist |
| Target | LH receptor (LHCGR) |
| Modality | Small molecule |
| Therapeutic area | Reproductive Medicine / Fertility |
| Phase | FDA-approved |
Mechanism of action
r-hCG alfa mimics the natural LH surge that occurs mid-cycle to complete meiosis I and trigger ovulation of the mature oocyte. It is used in assisted reproductive technology protocols after follicle-stimulating hormone (FSH) stimulation to induce final egg maturation and prepare the ovary for egg retrieval.
Approved indications
- Final oocyte maturation induction in women undergoing assisted reproductive technology (ART) such as in vitro fertilization (IVF)
- Ovulation induction in anovulatory women
Common side effects
- Ovarian hyperstimulation syndrome (OHSS)
- Headache
- Injection site reactions
- Abdominal pain/discomfort
- Nausea
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ovitrelle® [r-hCG alfa] CI brief — competitive landscape report
- Ovitrelle® [r-hCG alfa] updates RSS · CI watch RSS
- Merck KGaA, Darmstadt, Germany portfolio CI